Agenus Inc. (NASDAQ:AGEN - Get Free Report) has been given a consensus recommendation of "Hold" by the six brokerages that are covering the firm, Marketbeat.com reports. Five equities research analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $10.00.
Separately, HC Wainwright restated a "neutral" rating on shares of Agenus in a research report on Thursday, December 5th.
Check Out Our Latest Stock Report on AGEN
Institutional Trading of Agenus
Several large investors have recently bought and sold shares of AGEN. Point72 DIFC Ltd acquired a new stake in shares of Agenus during the 2nd quarter valued at $51,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Agenus during the second quarter worth about $106,000. EP Wealth Advisors LLC bought a new stake in shares of Agenus during the third quarter worth about $55,000. HighTower Advisors LLC increased its stake in shares of Agenus by 46.1% in the third quarter. HighTower Advisors LLC now owns 23,851 shares of the biotechnology company's stock valued at $122,000 after buying an additional 7,530 shares during the period. Finally, Blair William & Co. IL bought a new position in Agenus in the 2nd quarter valued at approximately $441,000. 61.46% of the stock is owned by institutional investors and hedge funds.
Agenus Stock Performance
Agenus stock traded down $0.22 during mid-day trading on Monday, reaching $2.83. The company's stock had a trading volume of 362,864 shares, compared to its average volume of 642,907. The business's 50 day simple moving average is $3.81 and its 200 day simple moving average is $7.40. Agenus has a 12 month low of $2.50 and a 12 month high of $19.69. The company has a market capitalization of $66.39 million, a price-to-earnings ratio of -0.27 and a beta of 1.24.
About Agenus
(
Get Free ReportAgenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
See Also
Before you consider Agenus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agenus wasn't on the list.
While Agenus currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
